Satellos Bioscience will use forazapadin as the international nonproprietary name for its lead candidate, previously known as SAT-3247. The name gives the therapy a globally recognized identity as it advances through clinical Duchenne muscular dystrophy studies and toward a planned FSHD trial by end of 2026.

Key Highlights

  • The World Health Organization naming process assigned forazapadin as the candidate’s globally recognized nonproprietary name.
  • Forazapadin inhibits AAK1, which Satellos identified as a protein involved in muscle repair and regeneration.
  • BASECAMP enrollment is expected to finish this quarter, with clinical data anticipated in the fourth quarter.

Satellos Bioscience Inc. (NASDAQ: MSLE) will use forazapadin as the international nonproprietary name for its lead drug candidate, previously known as SAT-3247. The orally administered small molecule is being evaluated in clinical studies for Duchenne muscular dystrophy, while Satellos intends to begin a trial in facioscapulohumeral muscular dystrophy by end of 2026.

WHO Name Establishes Forazapadin Identity

The World Health Organization naming process assigned the new name as the candidate moves through clinical development and toward potential commercialization. Satellos said the program will transition to broader use of forazapadin in future scientific, regulatory and corporate communications.

BASECAMP Milestones Remain Ahead

Satellos expects enrollment in the global BASECAMP study to be completed during the current quarter, with clinical data expected in the fourth quarter. BASECAMP is a randomized, placebo-controlled study involving pediatric participants, while TRAILHEAD is an open-label study in adults with Duchenne muscular dystrophy.